Analysts forecast that Becton Dickinson and Co (NYSE:BDX) will announce earnings per share of $2.61 for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Becton Dickinson and’s earnings. The highest EPS estimate is $2.66 and the lowest is $2.54. Becton Dickinson and posted earnings of $2.30 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.5%. The firm is expected to report its next quarterly earnings report before the market opens on Thursday, May 3rd.
On average, analysts expect that Becton Dickinson and will report full year earnings of $10.95 per share for the current fiscal year, with EPS estimates ranging from $10.89 to $11.00. For the next fiscal year, analysts anticipate that the company will post earnings of $12.62 per share, with EPS estimates ranging from $12.44 to $12.86. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the business earned $2.33 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis.
Several research firms have recently commented on BDX. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. KeyCorp began coverage on Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price target for the company. Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Finally, Evercore ISI began coverage on Becton Dickinson and in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price target for the company. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $241.19.
NYSE BDX traded up $1.92 on Monday, reaching $225.37. The stock had a trading volume of 962,077 shares, compared to its average volume of 1,168,332. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and has a 12-month low of $175.66 and a 12-month high of $248.39. The stock has a market cap of $59,491.88, a P/E ratio of 23.77, a P/E/G ratio of 1.62 and a beta of 1.15.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.33%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s payout ratio is 31.65%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John E. Gallagher sold 5,346 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total value of $1,208,623.68. Following the completion of the transaction, the vice president now owns 9,391 shares of the company’s stock, valued at approximately $2,123,117.28. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock valued at $61,321,396 in the last quarter. 1.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Chemical Bank grew its holdings in Becton Dickinson and by 15.0% in the fourth quarter. Chemical Bank now owns 4,800 shares of the medical instruments supplier’s stock valued at $1,028,000 after purchasing an additional 625 shares during the last quarter. Green Square Capital LLC grew its holdings in Becton Dickinson and by 99.7% in the fourth quarter. Green Square Capital LLC now owns 4,998 shares of the medical instruments supplier’s stock valued at $1,070,000 after purchasing an additional 2,495 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in Becton Dickinson and by 44.0% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 23,384 shares of the medical instruments supplier’s stock valued at $5,006,000 after purchasing an additional 7,145 shares during the last quarter. Wagner Wealth Management LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at $154,000. Finally, D.B. Root & Company LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at $723,000. Hedge funds and other institutional investors own 83.41% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Becton Dickinson and Co (BDX) to Announce $2.61 EPS” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2018/04/14/zacks-brokerages-anticipate-becton-dickinson-and-co-bdx-to-announce-2-61-eps.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.